94 related articles for article (PubMed ID: 1676581)
1. Induction of in vitro resistance to 4'-epidoxorubicin and cis-dichlorodiammineplatinum in hepatoma cells.
Hall KS; Endresen L; Huitfeldt HS; Rugstad HE
Anticancer Res; 1991; 11(2):817-23. PubMed ID: 1676581
[TBL] [Abstract][Full Text] [Related]
2. Multifactorial molecular mechanisms are involved in resistance of preirradiated human cervix carcinoma cells to cis-dichlorodiammineplatinum (II) and vincristine.
Osmak M
Neoplasma; 1993; 40(2):97-101. PubMed ID: 8102478
[TBL] [Abstract][Full Text] [Related]
3. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
Schmidt W; Chaney SG
Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361
[TBL] [Abstract][Full Text] [Related]
4. Increased removal of DNA-bound platinum in a human ovarian cancer cell line resistant to cis-diamminedichloroplatinum(II).
Masuda H; Tanaka T; Matsuda H; Kusaba I
Cancer Res; 1990 Mar; 50(6):1863-6. PubMed ID: 2306738
[TBL] [Abstract][Full Text] [Related]
5. Resistance of in vitro grown IgM immunocytoma cells to cis-diamminedichloroplatinum (II) (cis-DDP) and cross-resistance to other DNA interacting drugs.
Vendrik CP; de Jong WH; Van der Minnen AC; Fichtinger-Schepman AM; Steerenberg PA; Schornagel JH
Anticancer Res; 1990; 10(2A):447-52. PubMed ID: 2346318
[TBL] [Abstract][Full Text] [Related]
6. Collateral resistance or sensitivity of human larynx carcinoma HEp2 cells resistant to cis-dichlorodiammineplatinum (II) or vincristine sulfate.
Osmak M
Neoplasma; 1992; 39(3):197-202. PubMed ID: 1528326
[TBL] [Abstract][Full Text] [Related]
7. Collateral sensitivity to thaliblastine and/or hyperthermia exhibited by a rat ovarian tumor cell line selected for resistance to cisplatin.
Chen G; Zeller WJ; Todorov DK
Anticancer Res; 1993; 13(5A):1269-75. PubMed ID: 8239496
[TBL] [Abstract][Full Text] [Related]
8. cis-diamminedichloroplatinum(II)-resistant sublines derived from two human ovarian tumor cell lines.
Kuppen PJ; Schuitemaker H; van 't Veer LJ; de Bruijn EA; van Oosterom AT; Schrier PI
Cancer Res; 1988 Jun; 48(12):3355-9. PubMed ID: 2897238
[TBL] [Abstract][Full Text] [Related]
9. Effect of cis- and trans-dichlorodiammineplatinum(II) on human tumor cell proliferation in diffusion chambers in vivo.
Ambrose KR; Lowrey JS
Cancer Res; 1982 May; 42(5):1769-73. PubMed ID: 7039818
[TBL] [Abstract][Full Text] [Related]
10. [Establishment of a human nasopharyngeal carcinoma drug-resistant cell line CNE2/DDP and screening of drug-resistant genes].
Jiang RD; Zhang LX; Yue W; Zhu YF; Lu HJ; Liu X; Cen XT; Guan XY; Li CH
Ai Zheng; 2003 Apr; 22(4):337-45. PubMed ID: 12703984
[TBL] [Abstract][Full Text] [Related]
11. Correlation between cell killing by cis-diamminedichloroplatinum(II) in six mammalian cell lines and binding of a cis-diamminedichloroplatinum(II)-DNA antiserum.
Terheggen PM; Emondt JY; Floot BG; Dijkman R; Schrier PI; den Engelse L; Begg AC
Cancer Res; 1990 Jun; 50(12):3556-61. PubMed ID: 2340504
[TBL] [Abstract][Full Text] [Related]
12. Establishment and serial quantification of intrahepatic xenografts of human hepatocellular carcinoma in severe combined immunodeficiency mice, and development of therapeutic strategies to overcome multidrug resistance.
Leveille-Webster CR; Arias IA
Clin Cancer Res; 1996 Apr; 2(4):695-706. PubMed ID: 9816220
[TBL] [Abstract][Full Text] [Related]
13. Characterization of acquired resistance to cis-diamminedichloroplatinum (II) in BE human colon carcinoma cells.
Fram RJ; Woda BA; Wilson JM; Robichaud N
Cancer Res; 1990 Jan; 50(1):72-7. PubMed ID: 2293559
[TBL] [Abstract][Full Text] [Related]
14. Loss of cis-diamminedichloroplatinum(II) resistance in human ovarian carcinoma cells selected for rhodamine 123 resistance.
Zinkewich-Péotti K; Andrews PA
Cancer Res; 1992 Apr; 52(7):1902-6. PubMed ID: 1551119
[TBL] [Abstract][Full Text] [Related]
15. Single step selection of cis-diamminedichloroplatinum(II) resistant mutants from a human ovarian carcinoma cell line.
McLaughlin K; Stephens I; McMahon N; Brown R
Cancer Res; 1991 Apr; 51(8):2242-5. PubMed ID: 1901242
[TBL] [Abstract][Full Text] [Related]
16. [Establishment of human ovarian cancer cisplatin resistant cell line COC1/DDP and its mechanism of resistance].
Zhou Y; Chen H; Yang Q
Zhonghua Yi Xue Za Zhi; 1996 Sep; 76(9):680-3. PubMed ID: 9275551
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin.
Jain N; Lam YM; Pym J; Campling BG
Cancer; 1996 May; 77(9):1797-808. PubMed ID: 8646677
[TBL] [Abstract][Full Text] [Related]
18. [Mechanisms for resistance and cross-resistance patterns of cisplatin-resistant tumor lines].
Tashiro T
Gan To Kagaku Ryoho; 1990 Mar; 17(3 Pt 2):509-14. PubMed ID: 2321979
[TBL] [Abstract][Full Text] [Related]
19. Characterization of a human squamous carcinoma cell line resistant to cis-diamminedichloroplatinum(II).
Teicher BA; Holden SA; Kelley MJ; Shea TC; Cucchi CA; Rosowsky A; Henner WD; Frei E
Cancer Res; 1987 Jan; 47(2):388-93. PubMed ID: 3539321
[TBL] [Abstract][Full Text] [Related]
20. cis-Diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells.
Andrews PA; Velury S; Mann SC; Howell SB
Cancer Res; 1988 Jan; 48(1):68-73. PubMed ID: 3335000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
